Drug Pricing, Hospital Mark-ups and Judicial Intervention
The Hindu
Loading page, please wait…
The Supreme Court has taken strong exception to the massive gap between the Maximum Retail Price (MRP) and Price to Retailer (PTR) for cancer drugs, where mark-ups can reach up to 1,000%. Private hospitals leverage captive on-house pharmacies to extract exorbitant profits, bypassing existing price controls. This editorial analyzes the regulatory loopholes in the Drug (Prices Control) Order, 2013, and advocates for a fixed, regressive mark-up structure, extended price ceilings, and empowered oversight by the NPPA to make essential healthcare affordable.
The editorial examines the Supreme Court's critical observations regarding the staggering disparities between the Maximum Retail Price (MRP) and the Price to Retailer (PTR) of oncology medicines. It exposes how private hospitals exploit loopholes in regulatory frameworks by securing low PTRs and billing patients at high statutory MRPs, often mandating purchases from in-house pharmacies. This practice imposes catastrophic health expenditures on cancer patients. The editorial highlights the limitations of the Drug (Prices Control) Order, 2013, which caps ceiling prices without adequately regulating hospital-to-patient trade margins. Judicial activism in this context highlights systemic governance gaps within India's healthcare pricing architecture. To resolve this, regulatory bodies like the National Pharmaceutical Pricing Authority (NPPA) must be empowered to enforce regressive mark-up structures across all channels. In UPSC preparation, this issue intersects governance, judicial overreach versus judicial intervention, and health economics, making it a high-yield topic for analytical papers.
Connects to GS-2 (Issues relating to development and management of Social Sector/Services relating to Health) and GS-3 (Effects of liberalization on the economy, pricing policy). It offers a classic case study on regulatory failure, corporate ethics in healthcare, and the role of judicial interventions in protecting fundamental rights.
Highly relevant for GS-2 (Government policies and interventions for development in sectors arising out of design and implementation, issues relating to health) and GS-3 (Economics of healthcare, market regulation). Useful for questions on out-of-pocket expenditure and regulatory bodies like NPPA.